S. Jill James
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: West Los Angeles College (1988–1991); Arkansas Children's Hospital (2003–2020); NewYork–Presbyterian Brooklyn Methodist Hospital (2003); University of British Columbia (2003–2007); Johns Hopkins University (2017); University of California, Los Angeles (1990); Queen Mary University of London (2013); Duke University (2011); Cornell University (2003); Heidelberg University (2004–2011); Veterans Health Administration (2004); London Bridge Hospital (2022); University Hospital Heidelberg (2004); University of Florida (2011); Fred Hutch Cancer Center (2011); Grimsby Institute (2023); VA West Los Angeles Medical Center (1990–1991); Geriatric Research Education and Clinical Center (1990); King's College Hospital NHS Foundation Trust (2019); National Center for Tumor Diseases (2011); Cancer Research Center (2011); Tampere University (2002); King's College Hospital (2020–2022); UCLA Jonsson Comprehensive Cancer Center (1993); University of California, Davis (1996–2002); University of California, Berkeley (2011)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
S. Jill James' research focuses on the examination of associations between prenatal biomarkers of oxidative stress and offspring neurodevelopmental outcomes. Her work also investigates the role of oxidative stress in conditions such as Autism Spectrum Disorder (ASD) and its potential modifiable risk factors. James has led a randomized controlled trial exploring the effects of sulforaphane and metabolite discovery in children with ASD, with findings published in 2021 and a correction published in the same year. Her recent publications also include observational studies on postural tachycardia syndrome (PoTS) in post-COVID-19 patients and the relationship between prenatal oxidative stress markers like isoprostanes and neurodevelopment at 36 months of age.
With an h-index of 68 and over 14,800 citations across 172 publications, James has a significant scholarly record. Her collaborators include Stepan Melnyk from the University of Arkansas for Medical Sciences, with whom she shares three publications. Her research interests align with understanding disease mechanisms, particularly in the context of maternal and perinatal health, child and adolescent health, and metabolic and genetic disorders. Her work contributes to the broader field of health and medical research impacts.
Metrics
- h-index: 69
- Publications: 172
- Citations: 14,966
Selected Publications
-
The association between prenatal oxidative stress levels measured by isoprostanes and offspring neurodevelopmental outcomes at 36 months (2024)
-
Examining associations between prenatal biomarkers of oxidative stress and ASD-related outcomes using quantile regression (2022)
-
Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder (2021)
-
Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder (2021)
-
Altered Metabolism of Mothers of Young Children with Autism Spectrum Disorder: A Case Control Study (2020)
-
Altered Metabolism of Mothers of Young Children with Autism Spectrum Disorder: A Case Control Study (2020)
-
Altered Metabolism of Mothers of Young Children with Autism Spectrum Disorder: A Case Control Study (2020)
-
Altered Metabolism of Mothers of Young Children with Autism Spectrum Disorder: A Case Control Study (2020)
-
Altered Metabolism of Mothers of Young Children with Autism Spectrum Disorder: A Case Control Study (2020)
-
Altered Metabolism of Mothers of Young Children with Autism Spectrum Disorder: A Case Control Study (2020)
-
Altered metabolism of mothers of young children with Autism Spectrum Disorder: a case control study (2020)
-
Expression Changes in Epigenetic Gene Pathways Associated With One‐Carbon Nutritional Metabolites in Maternal Blood From Pregnancies Resulting in Autism and Non‐Typical Neurodevelopment (2020)
-
Expression changes in immune and epigenetic gene pathways associated with nutritional metabolites in maternal blood from pregnancies resulting in autism and atypical neurodevelopment (2020)
-
Comparison of Three Clinical Trial Treatments for Autism Spectrum Disorder Through Multivariate Analysis of Changes in Metabolic Profiles and Adaptive Behavior (2018)
-
Maternal metabolic profile predicts high or low risk of an autism pregnancy outcome (2018)
Collaboration Network
Top Collaborators
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Examining associations between prenatal biomarkers of oxidative stress and ASD-related outcomes using quantile regression
- The association between prenatal oxidative stress levels measured by isoprostanes and offspring neurodevelopmental outcomes at 36 months
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- Examining associations between prenatal biomarkers of oxidative stress and ASD-related outcomes using quantile regression
- The association between prenatal oxidative stress levels measured by isoprostanes and offspring neurodevelopmental outcomes at 36 months
- Examining associations between prenatal biomarkers of oxidative stress and ASD-related outcomes using quantile regression
- The association between prenatal oxidative stress levels measured by isoprostanes and offspring neurodevelopmental outcomes at 36 months
- Examining associations between prenatal biomarkers of oxidative stress and ASD-related outcomes using quantile regression
- The association between prenatal oxidative stress levels measured by isoprostanes and offspring neurodevelopmental outcomes at 36 months
- Examining associations between prenatal biomarkers of oxidative stress and ASD-related outcomes using quantile regression
- The association between prenatal oxidative stress levels measured by isoprostanes and offspring neurodevelopmental outcomes at 36 months
Similar Researchers
Based on overlapping research topics